We are convinced that a detailed mechanistic understanding of the molecular mechanisms underlying metabolic cell death or leaving a vulnerability to these forms of cell death will provide us unique opportunities to combat these often fatal diseases.

Our institute uses genome-wide genetic suppressor screens to unravel novel genes and players that essentially contribute to metabolic forms of cell death including ferroptosis lipotoxicity and others. This knowledge is key for the identification and preclinical development of novel small molecule compounds to target these key players of cell death. In vivo pharmacological approaches using genetic disease models of disease ultimately allow us to validate the in vivo relevance of pharmacological targeting of key nodes of cell death.